When playing the NK cell therapy card in glioblastoma, you can't beat interleukin-21.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE
    • Publication Information:
      Original Publication: Cambridge, Mass. : Cell Press, c2002-
    • Subject Terms:
      Glioblastoma*/immunology ; Glioblastoma*/therapy ; Killer Cells, Natural*/immunology ; Brain Neoplasms*/immunology ; Brain Neoplasms*/therapy ; Interleukins*/metabolism ; Interleukins*/immunology; Humans
    • Abstract:
      Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al. 1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
      Competing Interests: Declaration of interests N.D.H. reports stock or other ownership in oNKo-Innate and serves on advisory boards for Bristol Myers Squibb and Syena. N.D.H. is an inventor on multiple patents related to using adoptive NK cell therapy for cancer and targeting IL-15R signaling for cancer therapy.
      (Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.)
    • Accession Number:
      0 (Interleukins)
      MKM3CA6LT1 (interleukin-21)
    • Publication Date:
      Date Created: 20240813 Date Completed: 20240813 Latest Revision: 20240813
    • Publication Date:
      20240814
    • Accession Number:
      10.1016/j.ccell.2024.07.003
    • Accession Number:
      39137725